Segesterone acetate/ethinylestradiol

Ethinylestradiol /
segesterone acetate

Ethinylestradiol (top) and segesterone acetate (bottom)
Combination of
Ethinylestradiol	Estrogen
Segesterone acetate	Progestogen
Clinical data
Trade names	Annovera
Other names	EE/SGA; EE/SA
Routes of administration	Vaginal ring
Identifiers
KEGG	D11654

Ethinylestradiol/segesterone acetate (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains ethinylestradiol, an estrogen, and segesterone acetate, a progestin. It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.

Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for 7 days, during which the user experiences a period (withdrawal bleeding.) This can be repeated 13 times, for one full year of use. Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed to a patient and can be stored at temperatures up to 30 degrees Celsius.

The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for use in the United States on 10 August 2018.

See also

• Combined injectable birth control § Available forms
• List of combined sex-hormonal preparations